Cited by 601Blood Pressure and Hypertension StudiesCardiovascular Syncope and Autonomic DisordersHeart Rate Variability and Autonomic Control

Baroreflex Activation Therapy Lowers Blood Pressure in Patients With Resistant Hypertension

Open access
Bisognano, John D., Bakris, George, Nadim, Mitra K., Sanchez, Luis, Kroon, Abraham A., Schafer, Jill, de Leeuw, Peter W., Sica, Domenic A.·2011·Journal of the American College of Cardiology

Abstract

Objectives We sought to determine the effect of baroreflex activation therapy (BAT) on systolic blood pressure (SBP) in patients with resistant hypertension.Background The Rheos Pivotal Trial evaluated BAT for resistant hypertension in a double-blind, randomized, prospective, multicenter, placebo-controlled Phase III clinical trial.Methods This was a double-blind randomized trial of 265 subjects with resistant hypertension implanted and subsequently randomized (2:1) 1 month after implantation. Subjects received either BAT (Group A) for the first 6 months or delayed BAT initiation following the 6-month visit (Group B). The 5 coprimary endpoints were: 1) acute SBP responder rate at 6 months; 2) sustained responder rate at 12 months; 3) procedure safety; 4) BAT safety; and 5) device safety.Results The trial showed significant benefit for the endpoints of sustained efficacy, BAT safety, and device safety. However, it did not meet the endpoints for acute responders or procedural safety. A protocol-specified ancillary analysis showed 42% (Group A) versus 24% (Group B) achieving SBP ≤140 mm Hg at 6 months (p = 0.005), with both groups achieving over 50% at 12 months, at which point Group B had received 6 months of BAT.Conclusions A clinically meaningful measure, those achieving a SBP of ≤140 mm Hg, yielded a significant difference between the groups. The weight of the overall evidence suggests that over the long-term, BAT can safely reduce SBP in patients with resistant hypertension. Future clinical trials will address the limitations of this study and further define the therapeutic benefit of BAT.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2011.06.008

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Two device-based therapies targeting the sympathetic nervous system were developed: the surgically implanted barostimulator device and catheter-based renal denervation.

    “This was the development of two device-based therapies targeting the sympathetic nervous system, the surgically implanted barostimulator device117 and catheter-based renal denervation20,118.”
  • Despite the widespread availability and prescribing of angiotensin converting enzyme-inhibitors, angiotensin receptor blockers, diuretics and calcium channel blockers, in a substantial minority of patients with essential hypertension, perhaps 10%, goal blood pressure was not achieved.

    “Despite the widespread availability and prescribing of angiotensin converting enzyme-inhibitors, angiotensin receptor blockers, diuretics and calcium channel blockers, in a substantial minority of patients with essential hypertension, perhaps 10%116, goal blood pressure were not achieved.”
  • In a large-scale, double-blind study, the Rheos device was implanted in 265 patients who were subsequently randomised (2:1) to immediate baroreceptor stimulation for the first 6 months (n=181), or deferred stimulation after 6 months (n=84).

    “In a large-scale, double-blind study, the Rheos device was implanted in 265 patients who were subsequently randomised (2:1) to immediate baroreceptor stimulation for the first 6 months (n=181), or deferred stimulation after 6 months (n=84)117.”
  • At 6 months, blood pressure fell in the group receiving immediate treatment, but the primary efficacy endpoint was not reached, partly because blood pressure likewise decreased in many control subjects.

    “At 6 months, blood pressure fell in the group receiving immediate treatment, but the primary efficacy endpoint was not reached, partly because blood pressure likewise decreased in many control subjects117.”
  • The first results from a large randomized trial in 322 participants with resistant hypertension failed to meet the primary end point, a composite of 5 individual efficacy and safety end points.

    “The first results from a large randomized trial in 322 participants with RH410 failed to meet the primary end point of the trial, a composite of 5 individual efficacy and safety end points.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Bisognano, J. D., Bakris, G., Nadim, M. K., Sanchez, L., Kroon, A. A., Schafer, J., de Leeuw, P. W., & Sica, D. A.
Affiliations
  • University of Rochester Medicine (US)
  • University of Chicago (US)
  • University of Southern California (US)
  • Maastricht University Medical Centre (NL)
  • Virginia Commonwealth University (US)
Corresponding author
Bisognano, John D.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2011-08
Volume
58
Issue
7
Pages
765-773
ISSN
0735-1097 (ISSN-L)
OpenAlex
W167701172
Cited by
600
References
16
Citations by year
2026: 16 · 2025: 18 · 2024: 29 · 2023: 31 · 2022: 20 · 2021: 19 · 2020: 30 · 2019: 32 · 2018: 34 · 2017: 46 · 2016: 53 · 2015: 62 · 2014: 71 · 2013: 61 · 2012: 64
FWCI
45.97
Type
journal article
Language
en
Open access
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion, other-oa)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
Funders
CVRx
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Surgery › Cardiovascular Syncope and Autonomic Disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
Keywords
baroreflex activation therapy, resistant hypertension, systolic blood pressure, blood pressure reduction, device safety, procedural safety, antihypertensive therapy
MeSH terms
Blood Pressure, Carotid Sinus, Double-Blind Method, Electrodes, Implanted, Electric Stimulation Therapy, Female, Humans, Hypertension, Male, Middle Aged, Baroreflex

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review